JSE-listed local pharmaceutical manufacturers Aspen Pharmacare and Adcock Ingram say the coronavirus outbreak in China poses no immediate risk to production, as they have buffer stocks of imports used to formulate essential drugs.

The new respiratory illness, known as 2019-nCov, has sickened more than 40,500 people and killed more than 900 since it was first reported to the World Health Organisation (WHO) in late December, according to its latest assessment. The majority of the cases are in the epicentre of the outbreak in Wuhan, in China’s Hubei province, but 27 other countries had also confirmed cases by 4pm on Monday...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.